250
Participants
Start Date
February 8, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Nitric Oxide
Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Placebo
This is the placebo group. Nitrogen will be added instead of nitric oxide.
Massachusetts General Hospital, Boston
Ichinose, Fumito, M.D., Ph.D., Massachusetts General Hospital
UNKNOWN
Kenneth, Shelton, M.D., Massachusetts General Hospital
UNKNOWN
Kacmarek, Robert M., Ph.D., Massachusetts General Hospital
UNKNOWN
Sundt, Thoralf M., M.D., Massachusetts General Hospital
UNKNOWN
Villavicencio-Theoduloz, Mauricio A., M.D., Massachusetts General Hospital
UNKNOWN
Thompson, Boyd Taylor, M.D., Massachusetts General Hospital
UNKNOWN
Bonventre, Joseph V., M.D., Brigham Women Hospital
UNKNOWN
Shann, Kenneth G., Massachusetts General Hospital
UNKNOWN
Zapol, Warren M., M.D.
INDIV
Marrazzo, Francesco, M.D., Massachusetts General Hospital
UNKNOWN
Spina, Stefano, M.D., Massachusetts General Hospital
UNKNOWN
Zadek, Francesco, M.D., Massachusetts General Hospital
UNKNOWN
Rezoagli, Emanuele, M.D., Massachusetts General Hospital
UNKNOWN
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Massachusetts General Hospital
OTHER